BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shih YH, Peng CL, Lee SY, Chiang PF, Yao CJ, Lin WJ, Luo TY, Shieh MJ. 111In-cetuximab as a diagnostic agent by accessible epidermal growth factor (EGF) receptor targeting in human metastatic colorectal carcinoma. Oncotarget 2015;6:16601-10. [PMID: 26062654 DOI: 10.18632/oncotarget.3968] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Wollman AJM, Fournier C, Llorente-Garcia I, Harriman O, Payne-Dwyer AL, Shashkova S, Zhou P, Liu TC, Ouaret D, Wilding J, Kusumi A, Bodmer W, Leake MC. Critical roles for EGFR and EGFR-HER2 clusters in EGF binding of SW620 human carcinoma cells. J R Soc Interface 2022;19:20220088. [PMID: 35612280 DOI: 10.1098/rsif.2022.0088] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Raana G, Shah SQ. Synthesis of 111 In- p -SCN-Bn-DTPA-nimotuzumab and its preclinical evaluation in EGFR positive NSCLC animal model. Radiochimica Acta 2021;109:905-13. [DOI: 10.1515/ract-2021-1054] [Reference Citation Analysis]
3 Qiu L, Lin Q, Si Z, Tan H, Liu G, Zhou J, Wang T, Chen Y, Huang Y, Yu T, Jin M, Cheng D, Shi H. A Pretargeted Imaging Strategy for EGFR-Positive Colorectal Carcinoma via Modulation of Tz-Radioligand Pharmacokinetics. Mol Imaging Biol 2021;23:38-51. [PMID: 32914391 DOI: 10.1007/s11307-020-01539-z] [Reference Citation Analysis]
4 Benedetto R, Massicano AVF, Crenshaw BK, Oliveira R, Reis RM, Araújo EB, Lapi SE. 89Zr-DFO-Cetuximab as a Molecular Imaging Agent to Identify Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma. Cancer Biother Radiopharm 2019;34:288-96. [PMID: 30865493 DOI: 10.1089/cbr.2018.2616] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
5 Chang YJ, Ho CL, Cheng KH, Kuo WI, Lee WC, Lan KL, Chang CH. Biodistribution, pharmacokinetics and radioimmunotherapy of 188Re-cetuximab in NCI-H292 human lung tumor-bearing nude mice. Invest New Drugs 2019;37:961-72. [PMID: 30612308 DOI: 10.1007/s10637-018-00718-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
6 Liu X, Lukowski JK, Flinders C, Kim S, Georgiadis RA, Mumenthaler SM, Hummon AB. MALDI-MSI of Immunotherapy: Mapping the EGFR-Targeting Antibody Cetuximab in 3D Colon-Cancer Cell Cultures. Anal Chem 2018;90:14156-64. [PMID: 30479121 DOI: 10.1021/acs.analchem.8b02151] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
7 Cheng CC, Liao PN, Ho AS, Lim KH, Chang J, Su YW, Chen CG, Chiang YW, Yang BL, Lin HC, Chang YC, Chang CC, Chang YF. STAT3 exacerbates survival of cancer stem-like tumorspheres in EGFR-positive colorectal cancers: RNAseq analysis and therapeutic screening. J Biomed Sci 2018;25:60. [PMID: 30068339 DOI: 10.1186/s12929-018-0456-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
8 Bellaye PS, Moreau M, Raguin O, Oudot A, Bernhard C, Vrigneaud JM, Dumont L, Vandroux D, Denat F, Cochet A, Brunotte F, Collin B. Radiolabeled F(ab')2-cetuximab for theranostic purposes in colorectal and skin tumor-bearing mice models. Clin Transl Oncol 2018;20:1557-70. [PMID: 29777377 DOI: 10.1007/s12094-018-1886-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wang L, Yang D, Tian J, Gao A, Shen Y, Ren X, Li X, Jiang G, Dong T. Tumor necrosis factor receptor 2/AKT and ERK signaling pathways contribute to the switch from fibroblasts to CAFs by progranulin in microenvironment of colorectal cancer. Oncotarget 2017;8:26323-33. [PMID: 28412748 DOI: 10.18632/oncotarget.15461] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
10 Tsai MH, Pan CH, Peng CL, Shieh MJ. Panitumumab-Conjugated Pt-Drug Nanomedicine for Enhanced Efficacy of Combination Targeted Chemotherapy against Colorectal Cancer. Adv Healthc Mater 2017;6. [PMID: 28418176 DOI: 10.1002/adhm.201700111] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
11 Shih Y, Luo T, Chiang P, Yao C, Lin W, Peng C, Shieh M. EGFR-targeted micelles containing near-infrared dye for enhanced photothermal therapy in colorectal cancer. Journal of Controlled Release 2017;258:196-207. [DOI: 10.1016/j.jconrel.2017.04.031] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
12 Cataldi M, Vigliotti C, Mosca T, Cammarota M, Capone D. Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes. Int J Mol Sci 2017;18:E1249. [PMID: 28604595 DOI: 10.3390/ijms18061249] [Cited by in Crossref: 83] [Cited by in F6Publishing: 102] [Article Influence: 16.6] [Reference Citation Analysis]
13 Chen JL, Tsai Y, Tsai M, Lee S, Wei M, Kuo S, Shieh M. Prominin-1-Specific Binding Peptide-Modified Apoferritin Nanoparticle Carrying Irinotecan as a Novel Radiosensitizer for Colorectal Cancer Stem-Like Cells. Part Part Syst Charact 2017;34:1600424. [DOI: 10.1002/ppsc.201600424] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]